SAN FRANCISCO CHRONICLE
Drug patents don't ensure innovation
The Indian Supreme Court denied the pharmaceutical company Novartis a patent for its cancer drug Gleevec on April 1. Hailed by some as a victory for ensuring widespread access to lifesaving medications, the decision is derided by the pharmaceutical industry as counteractive to the discovery of new medicines. Both positions are based on an incomplete view of what promotes innovation.